Fluphenazine (oral) versus atypical antipsychotics for schizophrenia

Sampford, James; Sampson, Stephanie; Li, Bao Guo; Zhao, Shuo; Xia, Jun; Furtado, Vivek

doi:10.1002/14651858.cd010832.pub2

Cited by 5 publications

(1 citation statement)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to psychosocial treatment and the examination discussed above, drug therapy was a large issue. New psychotropic agents, including second generation antipsychotics (SGA), newer antidepressants and newer mood stabilizers, have been much more expensive than the traditional agents, but the newer agents have not proven to be more effective than the traditional agents (Sampford, Sampson, & Li, 2016;Saha, Bo, & Zhao, 2016Bauer, Severus, & Möller, 2017). If a hospital used the more expensive newer drugs, it did not promise a better outcome but this would result in large increases in hospital spending.…”

Section: Discussionmentioning

confidence: 99%

Mortality and rehospitalization rates among patients with severe mental illness (SMI) at different levels of hospital spending

Lin

Tsai

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Evidence has shown that the relationships between hospital spending and treatment outcomes for physical conditions have been inconclusive. So to investigate the association between hospital spending and both risk-adjusted mortality and rehospitalization rates among patients with severe mental illness (SMI). Method This was a retrospective cohort study that used the Taiwan National Health Research Institute Database (NHRID) from 1999 to 2010. Hospital end-of-life (EOL) spending was used to quantify hospital spending and was determined by the total medical costs of the last year of life of patients with at least one previous psychiatric hospitalization. Patients with schizophrenia (n=13,229), bipolar disorder (n=4,476) and major depressive disorder (n=5,177) were followed for mortality and rehospitalization to psychiatric wards from 2009 to 2010 after they had been discharged from the study hospitals. Results Patients with schizophrenia had lower rehospitalization and mortality rates when treated at higher-spending hospitals than when treated at the lowest-spending hospitals. However, these associations became weak, even nonsignificant, when adjusted for patient-level variables. There were no significant findings for patients with bipolar disorder and major depressive disorder when patient-level variables were adjusted for. Patient-level variables showed more determinant roles than hospital-level variables in the relationships between hospital spending and treatment outcomes. Conclusion Hospitals that spend more at the EOL had lower mortality and rehospitalization rates for patients with schizophrenia but higher rates for bipolar disorder and major depressive disorder. Most of these associations could be explained by patients’ characteristics more than hospitals’ characteristics.

show abstract

Section: Discussionmentioning

confidence: 99%